Global Antisense & RNAi Therapeutics 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12247986

Publication Date:

December 12, 2024

Pages:

128

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Antisense & RNAi Therapeutics market size was valued at US$ 937.7 million in 2023. With growing demand in downstream market, the Antisense & RNAi Therapeutics is forecast to a readjusted size of US$ 1268.5 million by 2030 with a CAGR of 4.4% during review period.
The research report highlights the growth potential of the global Antisense & RNAi Therapeutics market. Antisense & RNAi Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Antisense & RNAi Therapeutics. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Antisense & RNAi Therapeutics market.
Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene "off".
North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.
Key Features:
The report on Antisense & RNAi Therapeutics market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Antisense & RNAi Therapeutics market. It may include historical data, market segmentation by Type (e.g., RNA Interference, SiRNA), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Antisense & RNAi Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Antisense & RNAi Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Antisense & RNAi Therapeutics industry. This include advancements in Antisense & RNAi Therapeutics technology, Antisense & RNAi Therapeutics new entrants, Antisense & RNAi Therapeutics new investment, and other innovations that are shaping the future of Antisense & RNAi Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Antisense & RNAi Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Antisense & RNAi Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Antisense & RNAi Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Antisense & RNAi Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Antisense & RNAi Therapeutics market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Antisense & RNAi Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Antisense & RNAi Therapeutics market.
麻豆原创 Segmentation:
Antisense & RNAi Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
RNA Interference
SiRNA
MiRNA
Antisense RNA
Segmentation by application
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Antisense & RNAi Therapeutics 麻豆原创 Size 2019-2030
2.1.2 Antisense & RNAi Therapeutics 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Antisense & RNAi Therapeutics Segment by Type
2.2.1 RNA Interference
2.2.2 SiRNA
2.2.3 MiRNA
2.2.4 Antisense RNA
2.3 Antisense & RNAi Therapeutics 麻豆原创 Size by Type
2.3.1 Antisense & RNAi Therapeutics 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Antisense & RNAi Therapeutics 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Antisense & RNAi Therapeutics Segment by Application
2.4.1 Oncology
2.4.2 Cardiovascular
2.4.3 Renal
2.4.4 Neurodegenerative
2.4.5 Respiratory
2.4.6 Genetic
2.4.7 Infectious Diseases
2.5 Antisense & RNAi Therapeutics 麻豆原创 Size by Application
2.5.1 Antisense & RNAi Therapeutics 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Antisense & RNAi Therapeutics 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Antisense & RNAi Therapeutics 麻豆原创 Size by Player
3.1 Antisense & RNAi Therapeutics 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Antisense & RNAi Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Antisense & RNAi Therapeutics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Antisense & RNAi Therapeutics Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Antisense & RNAi Therapeutics by Regions
4.1 Antisense & RNAi Therapeutics 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Antisense & RNAi Therapeutics 麻豆原创 Size Growth (2019-2024)
4.3 APAC Antisense & RNAi Therapeutics 麻豆原创 Size Growth (2019-2024)
4.4 Europe Antisense & RNAi Therapeutics 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Antisense & RNAi Therapeutics 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Antisense & RNAi Therapeutics 麻豆原创 Size by Country (2019-2024)
5.2 Americas Antisense & RNAi Therapeutics 麻豆原创 Size by Type (2019-2024)
5.3 Americas Antisense & RNAi Therapeutics 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense & RNAi Therapeutics 麻豆原创 Size by Region (2019-2024)
6.2 APAC Antisense & RNAi Therapeutics 麻豆原创 Size by Type (2019-2024)
6.3 APAC Antisense & RNAi Therapeutics 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Antisense & RNAi Therapeutics by Country (2019-2024)
7.2 Europe Antisense & RNAi Therapeutics 麻豆原创 Size by Type (2019-2024)
7.3 Europe Antisense & RNAi Therapeutics 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antisense & RNAi Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Antisense & RNAi Therapeutics 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Antisense & RNAi Therapeutics 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.1 Global Antisense & RNAi Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Antisense & RNAi Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Antisense & RNAi Therapeutics Forecast
10.1.3 APAC Antisense & RNAi Therapeutics Forecast
10.1.4 Europe Antisense & RNAi Therapeutics Forecast
10.1.5 Middle East & Africa Antisense & RNAi Therapeutics Forecast
10.2 Americas Antisense & RNAi Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.2.2 Canada Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.2.3 Mexico Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.2.4 Brazil Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.3 APAC Antisense & RNAi Therapeutics Forecast by Region (2025-2030)
10.3.1 China Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.3.2 Japan Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.3.3 Korea Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.3.4 Southeast Asia Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.3.5 India Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.3.6 Australia Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.4 Europe Antisense & RNAi Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.4.2 France Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.4.3 UK Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.4.4 Italy Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.4.5 Russia Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.5 Middle East & Africa Antisense & RNAi Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.5.2 South Africa Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.5.3 Israel Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.5.4 Turkey Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.5.5 GCC Countries Antisense & RNAi Therapeutics 麻豆原创 Forecast
10.6 Global Antisense & RNAi Therapeutics Forecast by Type (2025-2030)
10.7 Global Antisense & RNAi Therapeutics Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Glaxo Smith Kline
11.1.1 Glaxo Smith Kline Company Information
11.1.2 Glaxo Smith Kline Antisense & RNAi Therapeutics Product Offered
11.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Glaxo Smith Kline Main Business Overview
11.1.5 Glaxo Smith Kline Latest Developments
11.2 Sanofi Aventis / Genzyme
11.2.1 Sanofi Aventis / Genzyme Company Information
11.2.2 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product Offered
11.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Sanofi Aventis / Genzyme Main Business Overview
11.2.5 Sanofi Aventis / Genzyme Latest Developments
11.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
11.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Information
11.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Main Business Overview
11.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Latest Developments
11.4 Arbutus Biopharma Ltd.
11.4.1 Arbutus Biopharma Ltd. Company Information
11.4.2 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product Offered
11.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Arbutus Biopharma Ltd. Main Business Overview
11.4.5 Arbutus Biopharma Ltd. Latest Developments
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Information
11.5.2 Silence Therapeutics Antisense & RNAi Therapeutics Product Offered
11.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Silence Therapeutics Main Business Overview
11.5.5 Silence Therapeutics Latest Developments
11.6 Bio-Path Holdings Inc.
11.6.1 Bio-Path Holdings Inc. Company Information
11.6.2 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product Offered
11.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Bio-Path Holdings Inc. Main Business Overview
11.6.5 Bio-Path Holdings Inc. Latest Developments
11.7 Calando Pharmaceuticals
11.7.1 Calando Pharmaceuticals Company Information
11.7.2 Calando Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Calando Pharmaceuticals Main Business Overview
11.7.5 Calando Pharmaceuticals Latest Developments
11.8 ICo Therapeutics
11.8.1 ICo Therapeutics Company Information
11.8.2 ICo Therapeutics Antisense & RNAi Therapeutics Product Offered
11.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 ICo Therapeutics Main Business Overview
11.8.5 ICo Therapeutics Latest Developments
11.9 Quark Pharmaceuticals
11.9.1 Quark Pharmaceuticals Company Information
11.9.2 Quark Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Quark Pharmaceuticals Main Business Overview
11.9.5 Quark Pharmaceuticals Latest Developments
11.10 Rexhan Pharmaceuticals
11.10.1 Rexhan Pharmaceuticals Company Information
11.10.2 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Rexhan Pharmaceuticals Main Business Overview
11.10.5 Rexhan Pharmaceuticals Latest Developments
11.11 Biomarin/Prosensa
11.11.1 Biomarin/Prosensa Company Information
11.11.2 Biomarin/Prosensa Antisense & RNAi Therapeutics Product Offered
11.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Biomarin/Prosensa Main Business Overview
11.11.5 Biomarin/Prosensa Latest Developments
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Information
11.12.2 Regulus Therapeutics Antisense & RNAi Therapeutics Product Offered
11.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Regulus Therapeutics Main Business Overview
11.12.5 Regulus Therapeutics Latest Developments
11.13 Rxi Pharmaceuticals
11.13.1 Rxi Pharmaceuticals Company Information
11.13.2 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Rxi Pharmaceuticals Main Business Overview
11.13.5 Rxi Pharmaceuticals Latest Developments
11.14 Silenseed
11.14.1 Silenseed Company Information
11.14.2 Silenseed Antisense & RNAi Therapeutics Product Offered
11.14.3 Silenseed Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Silenseed Main Business Overview
11.14.5 Silenseed Latest Developments
11.15 Dicerna Pharmaceuticals
11.15.1 Dicerna Pharmaceuticals Company Information
11.15.2 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product Offered
11.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 Dicerna Pharmaceuticals Main Business Overview
11.15.5 Dicerna Pharmaceuticals Latest Developments
11.16 Sirnaomics Inc.
11.16.1 Sirnaomics Inc. Company Information
11.16.2 Sirnaomics Inc. Antisense & RNAi Therapeutics Product Offered
11.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Sirnaomics Inc. Main Business Overview
11.16.5 Sirnaomics Inc. Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.